Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BURNING ROCK BIOTECH LIMITED

(BNR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Burning Rock Biotech : China's first NGS cancer testing kit made by Burning Rock Dx and licensed

09/14/2021 | 04:12am EDT
China's first NGS cancer testing kit made by Burning Rock Dx and licensed Var Date:2019-08-26

On July 23, 2018, National Medical Products Administration (NMPA) vetted and granted a license to Burning Rock Biotech(Guang Zhou) Co., Ltd. (hereinafter referred to as Burning Rock Dx) for making a creative high-throughput product - 'human-targeted EGFR/ALK/BRAF/KRAS polygene mutation testing kit (reversible terminator sequencing) (hereinafter referred to as 'the kit')'. The kit is a Class III medical equipment product.

The kit is China's first polygene tumor mutation testing kit based on high-throughput NGS and companion diagnostics standards approved, which will be an aid to non-small cell lung cancer patients for selecting precision targeted drug therapies. In September 2016, NMPA approved the kit to enter 'special approval procedures for creative medical equipment' as China's first NGS cancer testing product. And two years or so later, the NMPA ultimately granted the 'first NGS cancer testing product license' of profound significance after rigorous verification of mass clinical samples in clinical trials and vetting in the licensed product quality system.

Compared with traditional genetic testing methods, NGS informs patients of many cancer-therapy-related hotspots and non-hotspots in mutation panorama and covers point mutation, insertion loss and rearrangement (fusion) among other forms of variation to render a one-stop testing solution involving many targeted drugs to doctors and patients with fewer testing samples and shorter testing duration.

NGS has been accepted by clinicians in precision medicine and companion diagnostics. But as a sophisticated technology, NGS runs into quality system standardization and normalization bottlenecks in clinical routine. The license granted to Burning Rock Dx's kit marks that NGS cancer testing will be duly put into use in hospitals' clinical labs. Beyond doubt, it is a landmark in the march of making NGS benefit more cancer patients.

Meanwhile, Burning Rock Dx-CTONG Laboratory in Guangzhou was awarded a technical vetting qualification certificate for 'high-throughput sequencing lab' by National Center for Clinical Laboratories, National Health Commission in this May. Burning Rock Dx's NGS testing platform as a laboratory developed test (LDT) project provides clinical sample testing service for a variety of cancer patients that fall into more stages. At the moment, it is the only institution in China that has passed China's technical vetting on anti-cancer high-throughput sequencing labs and U.S. CLIA NGS lab certification for LDTs through a demanding review on its testing capacity in line with relevant national and international quality control regulations and systems.

Mr. Han Yusheng, Founder and CEO of Burning Rock Dx, said, 'Burning Rock Dx will keep devoting to developing professional, accurate and sensitive NGS cancer testing techniques. We'd appreciate relevant national regulators and specialists for unremitting effort in speeding up introducing outstanding creative techniques to clinical practice. In the future, we are confident and competent that we will make China's NGS industry more accurate and standardized and hike up industrial standards and benefit more cancer patients through tight cooperation with specialists in the industry. In addition, Burning Rock Dx is working on key techniques and developing early cancer screening products to further advance when cancers are diagnosed and contribute to higher rate of survival in cancer therapy.'

Disclaimer

Burning Rock Biotech Ltd. published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 08:11:02 UTC.


ę Publicnow 2021
All news about BURNING ROCK BIOTECH LIMITED
09/14BURNING ROCK BIOTECH : and CStone Pharmaceuticals reached a strategic collaboration on the..
PU
09/14BURNING ROCK BIOTECH : deepens cooperation with Illumina to promote development and standa..
PU
09/14BURNING ROCK BIOTECH : initiates the first prospective, multi-center pan-cancer early dete..
PU
09/14BURNING ROCK BIOTECH : Dx Launches Magnis BR to Innovate Total Process Automation for NGS ..
PU
09/14BURNING ROCK BIOTECH : announces the completion of the Series C financing of RMB 850 milli..
PU
09/14BURNING ROCK BIOTECH : China's first NGS cancer testing kit made by Burning Rock Dx and li..
PU
09/14BURNING ROCK BIOTECH : Dx Honored with 2018 Guangzhou Hi-tech “Unicorn” and &l..
PU
09/14BURNING ROCK BIOTECH : Dx Certified by the Certification of ISO 13485 Quality Management S..
PU
09/14BURNING ROCK BIOTECH : and Illumina Collaborate on Molecular Diagnostics for Oncology
PU
08/31SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Tuesday
MT
More news
Analyst Recommendations on BURNING ROCK BIOTECH LIMITED
More recommendations
Financials
Sales 2021 503 M 78,2 M 78,2 M
Net income 2021 -395 M -61,4 M -61,4 M
Net cash 2021 1 443 M 224 M 224 M
P/E ratio 2021 -24,3x
Yield 2021 -
Capitalization 9 659 M 1 501 M 1 501 M
EV / Sales 2021 16,3x
EV / Sales 2022 12,1x
Nbr of Employees 938
Free-Float 72,4%
Chart BURNING ROCK BIOTECH LIMITED
Duration : Period :
Burning Rock Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BURNING ROCK BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 92,39 CNY
Average target price 211,13 CNY
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Yu Sheng Han Chairman & Chief Executive Officer
Leo Li Chief Financial Officer & Director
Zhi Hong Zhang Chief Technology Officer
Shao Kun Chuai Chief Operating Officer & Director
Wendy Hayes Independent Director
Sector and Competitors